Safety and efficacy of different initial doses of lurasidone in the schizophrenia treatment: A multi-center, randomized, open-label study

Table 3 Summary of adverse events and adverse reactions (safety set), n (%), events

Category	Lurasidone (40 mg/day), n = 99	Lurasidone (80 mg/day), n = 98
Treatment-emergent adverse events	64 (64.6), 182	70 (71.4), 178
Serious adverse events (during the treatment)	1 (1.0), 1	4 (4.1), 4
Adverse reactions	53 (53.5), 122	56 (57.1), 115
Serious adverse reactions (during the treatment)	1 (1.0), 1	3 (3.1), 3
Adverse events leading to discontinuation of investigational product	3 (3.0), 3	5 (5.1), 5
Adverse events leading to dose reduction of investigational product	4 (4.0), 7	12 (12.2), 16
Adverse events leading to subject withdrawal from the trial	1 (1.0), 1	2 (2.0), 2
Adverse events leading to subject death	0, 0	0, 0